Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NCT06935136 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

CAR-T Cell Therapy
High-risk Large B-cell Lymphoma (LBCL)

Interventions

DRUG: Axicabtagene Ciloleucel

Sponsor

Ruijin Hospital